CLINICAL-FEATURES ASSOCIATED WITH TRANSFORMATION OF CEREBRIFORM T-CELL LYMPHOMA TO A LARGE CELL PROCESS

被引:55
作者
GREER, JP
SALHANY, KE
COUSAR, JB
FIELDS, JP
KING, LE
GRABER, SE
FLEXNER, JM
STEIN, RS
COLLINS, RD
机构
[1] VANDERBILT UNIV,MED CTR,DIV HEMATOPATHOL,NASHVILLE,TN 37232
[2] VANDERBILT UNIV,MED CTR,DEPT DERMATOL,NASHVILLE,TN 37232
[3] VANDERBILT UNIV,MED CTR,DEPT PATHOL,NASHVILLE,TN 37232
[4] VANDERBILT UNIV,MED CTR,DEPT MED,NASHVILLE,TN 37232
关键词
Cutaneous lymphoma; Transformation; T‐cell;
D O I
10.1002/hon.2900080406
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Some patients with cerebriform T‐cell lymphoma (CTCL) undergo morphologic transformation to a large cell lymphoma. From a series of 113 patients with CTCL, 22 patients were identified with transformed CTCL. Stages of involvement at diagnosis were: I (seven), II (four), III (four), IV (seven). Nine patients had transformation at the initial diagnosis while the median time from diagnosis to transformation in the other 13 patients was 16 months (range: 3 months–6 years). Thirteen had transformation extracutaneously: lymph nodes (eight), central nervous system (two), and other extranodal sites (three). T cell markers were identified in all cases; of 15 cases with complete phenotypes, there were eight T‐helper, three T‐suppressor, and four aberrant T phenotypes. Serology for human T‐leukemia virus‐I (HTLV‐I) was negative in eight patients tested. Median survival from diagnosis was 27 months compared to 53 months in 53 patients without transformation (p = 0.003). Despite combination chemotherapy in 12 patients following transformation, median survival after transformation was 12 months and only 7 months with extracutaneous disease. The likelihood of transformation could not be predicted by the initial histology, immunophenotype, or stage of disease. Copyright © 1990 John Wiley & Sons, Ltd
引用
收藏
页码:215 / 227
页数:13
相关论文
共 82 条
[51]  
RAPPAPORT H, 1974, CANCER-AM CANCER SOC, V34, P1198, DOI 10.1002/1097-0142(197410)34:4<1198::AID-CNCR2820340431>3.0.CO
[52]  
2-E
[53]  
SALHANY KE, 1988, AM J PATHOL, V132, P265
[54]   MORPHOLOGIC HETEROGENEITY OF MALIGNANT-LYMPHOMAS DEVELOPING IN MYCOSIS-FUNGOIDES [J].
SCHEEN, SR ;
BANKS, PM ;
WINKELMANN, RK .
MAYO CLINIC PROCEEDINGS, 1984, 59 (02) :95-106
[55]  
SCHEFFER E, 1980, CANCER, V45, P137, DOI 10.1002/1097-0142(19800101)45:1<137::AID-CNCR2820450124>3.0.CO
[56]  
2-K
[57]   BLEOMYCIN, ADRIAMYCIN, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNISONE (BACOP) COMBINATION CHEMOTHERAPY IN TREATMENT OF ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA [J].
SCHEIN, PS ;
DEVITA, VT ;
HUBBARD, S ;
CHABNER, BA ;
CANELLOS, GP ;
BERARD, C ;
YOUNG, RC .
ANNALS OF INTERNAL MEDICINE, 1976, 85 (04) :417-422
[58]  
SCHWARZE EW, 1975, VIRCHOWS ARCH PATHOL, V369, P265
[59]  
SHERROD AE, 1986, CANCER, V57, P2135, DOI 10.1002/1097-0142(19860601)57:11<2135::AID-CNCR2820571109>3.0.CO
[60]  
2-N